<DOC>
	<DOCNO>NCT00622687</DOCNO>
	<brief_summary>This study compare efficacy different dosage long-term iloprost treatment Raynaud 's phenomenon , ulcer healing , skin thickening , progression internal organ sclerosis systemic sclerosis ( SSc ) . Methods . 50 SSc patient 1:1 randomise either maximally tolerate dose 2 ng/kg body weight [ bw ] per minute low dose ( 0.5 ng/kg bw per minute ) intravenous iloprost administration , six hour daily 21 day . The effect RP , ulcer healing , skin thickness , oesophagus function , lung involvement assess lung function parameter FVC DLCO , side effect measure . Conclusions . The efficacy prolonged administration iloprost also achieve low dose iloprost long term treatment . The effect suggest disease-modifying capability iloprost , study need proof hypothesis .</brief_summary>
	<brief_title>Effect Different Iloprost Doses Symptoms Systemic Sclerosis</brief_title>
	<detailed_description>50 SSc patient ( 23 patient limited SSc ; 15 patient diffuse SSc , 12 patient overlap syndrome fulfil ACR criterion systemic sclerosis ) suffer severe Raynaud ` phenomenon include study write informed consent participate study . Severe Raynaud ` phenomenon defined high burden disease , trophic skin change , presence digital ulcer . Patients suffer SSc related RP and/or digital ulceration randomize 1 : 1 one follow group receive either high low dose infusion iloprost 21 consecutive day give twice year . High dose patient ( n=25 ) start 0.5ng per kg bw min 6 hour day . Depending tolerability dosage increase increment gradually every two day 0.5 ng/kg x min . The maximum dose administer 2.0ng/kg bw min . Low dose patient ( n=25 ) permanently treat 0.5ng/kg bw 6 hour per day 21 consecutive day .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>patient secondary Raynaud ` phenomenon suffering severe Raynaud ` phenomenon trophical change digital ulcer write informed consent . Patients stable systemic disease stable medication concern immunosuppression vasoactive therapy three month . Current smoker , patient history gastric ulcer last three month , cardiac ejection fraction 25 % , patient severe organ involvement uncontrolled disease instable angina pectoris , severe anaemia , coagulopathies , azothaemia , cerebral stroke last 6 month malignant disease exclude study . The last iloprost therapy finish least 6 month ago . Participation study last 4 week also allow . For fertile woman , negative pregnancy test require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>iloprost</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>digital ulcer</keyword>
	<keyword>observational study</keyword>
	<keyword>randomize</keyword>
</DOC>